press release

April 13, 2020

– RNAi Represents One of the Most Promising and Rapidly Advancing Frontiers in Biology and Drug Development Today with Potential to Transform Lives of Patients – – Blackstone Provides a Customized Investment at Scale to Enable Alnylam to Achieve Self sustainable Financial Profile Without Need for Future Equity Financing – – Alnylam to Host Conference Call Today, Monday, April 13th, at ...

news

March 30, 2020

Updated July 17, 2020 The COVID 19 pandemic is having a significant impact on people and communities all over the world and will continue to do so for an indefinite period. At Alnylam, we’re closely monitoring developments and guidance from governments and health authorities on a daily basis. We are making adjustments to our operations as needed to support the health ...

news

March 6, 2020

The theme of this year's International Women's Day is "Each for Equal" and asks everyone, regardless of gender identity how they're working to forge a gender equal world. This question, and the concept of a gender equality in the workplace are near and dear to our hearts at Alnylam. Diversity and inclusion is ingrained into the fabric our core values and ensuring ...

press release

February 18, 2020

– HELIOS A Topline Results Expected in Early 2021 – CAMBRIDGE, Mass. (BUSINESS WIRE) Feb. 18, 2020 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it has achieved full enrollment in its HELIOS A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis. The study was designed ...

press release

February 6, 2020

− Achieved Fourth Quarter and Full Year 2019 ONPATTRO® (patisiran) Global Net Product Revenues of $55.8 Million and $166.4 Million, Respectively – − As of Year End 2019, Over 750 Patients Worldwide Receiving Commercial ONPATTRO, with Over 1,000 Total Patients Worldwide Being Treated with Patisiran – – Observed Strong Initial Demand for GIVLAARI™ (givosiran) in the U.S., with 13 Start Forms ...

press release

December 17, 2019

− Lumasiran Met Primary and All Tested Secondary Endpoints, with Significant Reduction in Urinary Oxalate Levels Relative to Placebo – − Alnylam Intends to File New Drug Application (NDA) and Marketing Authorisation Application (MAA) in Early 2020 – − Full Results to be Presented at OxalEurope International Congress in March 2020 – − Alnylam to Host Conference Call Today at ...

press release

November 22, 2019

− Expects to Exceed Alnylam 2020 Goals with Four Marketed Products, 14 Organic Clinical Stage Programs, Including 6 in Late Stage Development, Across 4 Strategic Therapeutic Areas (STArs), by End of 2020 – – Initiates HELIOS B Phase 3 Study of Investigational Vutrisiran in ATTR Amyloidosis Cardiomyopathy – – Announces Initial Positive Clinical Results with ALN AAT02 and ALN HBV02 (VIR ...

capella

November 19, 2019

On November 22nd, 2019, we will be hosting an R&D Day in New York City. The event will showcase Alnylam’s late stage clinical efforts, next wave programs, and platform advances. The Company will also discuss its perspective on its transition toward achieving a self sustainable financial profile. To view the webcast, click here. A replay of the webcast will be ...

news

November 18, 2019

I joined Alnylam in May 2019, which makes me a newcomer relative to three quarters of our organization. However, having developed my career in the healthcare space over the last 20 years, I’ve watched Alnylam grow, and create a unique culture that appeals to very talented, high performing, mission driven people. Our culture, which was founded on passion for excellence, innovation ...

news

November 5, 2019

Nearly all biopharma companies will say that great science is at the heart of what they do. But what does that really mean? As a physician scientist and business leader at a company that in the past few years has begun the transition from biotech to commercial stage biopharma, that's something I've thought quite a lot about because maintaining our focus ...